On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Florence Joly

ResearcherPublications, citations & collaboration network

Florence Joly is a researcher indexed in ScholarIQ from OpenAlex & ORCID.

How many works does Florence Joly have?

ScholarIQindexed works

Florence Joly has 629 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Florence Joly have?

ScholarIQcitation count

Florence Joly has 23,633 citations in the OpenAlex counts ScholarIQ stores.

What is the h-index of Florence Joly?

ScholarIQh-index

Florence Joly has an h-index of 74 in OpenAlex.

What is the i10-index of Florence Joly?

ScholarIQi10-index

Florence Joly has an i10-index of 224 in OpenAlex.

What is the ORCID of Florence Joly?

ScholarIQorcid

The ORCID for Florence Joly is on the source record.

What is the OpenAlex record for Florence Joly?

ScholarIQopenalex

The OpenAlex for Florence Joly is on the source record.

What are the most-cited papers on Florence Joly?

ScholarIQmost cited works
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle, Val Gebski, Richard T. Penson, Amit M. Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata, Michael Friedländer, Nicoletta Colombo, Philipp Harter, Keiichi Fujiwara, Isabelle Ray‐Coquard, Susana Banerjee, Joyce F. Liu, Elizabeth Lowe, Ralph Bloomfield, Patricia Pautier, Jacob Korach, Tomasz Huzarski, Tomasz Byrski, Patricia Pautier, Michael Friedländer, Philipp Harter, Nicoletta Colombo, Sandro Pignata, Giovanni Scambia, Maria Ornella Nicoletto, Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano, Kian Behbakht, Susan A. Davidson
The Lancet Oncology. 20171,881 Citations
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Léary, Robert W. Holloway, Margarita Amenedo, Peter C.C. Fong, Jeffrey C. Goh, David M. O’Malley, Deborah K. Armstrong, Jesús García-Donás, Elizabeth M. Swisher, Anne Floquet, Gottfried E. Konecny, Iain A. McNeish, Clare L. Scott, T. Cameron, Lara Maloney, Jeff Isaacson, Sandra Goble, Caroline A. Grace, Thomas C. Harding, Mitch Raponi, James Sun, Kevin Lin, Heidi Giordano, Jonathan A. Ledermann, Martin Buck, Andrew Dean, Michael Friedländer, Jeffrey C. Goh, Paul R. Harnett, Ganessan Kichenadasse, Clare L. Scott, Hannelore Denys, Luc Dirix, Ignace Vergote, Laurie Elit, Prafull Ghatage, Amit M. Oza, Marie Plante, Diane Provencher, Johanne I. Weberpals, Stephen Welch, Anne Floquet, Laurence Gladieff, Florence Joly, Alexandra Léary, Alain Lortholary, Jean‐Pierre Lotz, Jacques Médioni, Olivier Trédan, Benoît You, Ayşe Balat, Claudia Hänle, Petra Krabisch, Tanja Neunhöffer, Martin Pölcher, Pauline Wimberger, A Amit, Svetlana Kovel, Michelle Leviov, Tamar Safra, Ronnie Shapira‐Frommer, Salomon M. Stemmer, Alessandra Bologna, Nicoletta Colombo, Domenica Lorusso, Sandro Pignata, Roberto Sabbatini, Giovanni Scambia, Stefano Tamberi, Claudio Zamagni, Peter C.C. Fong, Anne O’Donnell, Margarita Amenedo, A. Casado Herráez, Jesús García-Donás, E.M. Guerra, Ana Oaknin, Isabel Palacio, Ignacio Romero, A Sanchez, Susana Banerjee, Andrew R. Clamp, Yvette Drew, Hani Gabra, D Jackson, JA Ledermann, Iain A. McNeish, C. A. Parkinson, Melanie Powell, Carol Aghajanian
The Lancet. 20171,721 CitationsOPEN ACCESS
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Amit M. Oza, Adrian Cook, Jacobus Pfisterer, Andrew Embleton-Thirsk, Jonathan A. Ledermann, Éric Pujade-Lauraine, Gunnar B. Kristensen, Mark S. Carey, Philip Beale, Andrés Cervantes, Tjoung‐Won Park‐Simon, Gordon Rustin, Florence Joly, Mansoor Raza Mirza, Marie Plante, Michael Quinn, Andrés Poveda, Gordon C. Jayson, Dan Stark, Ann Marie Swart, Laura Farrelly, Richard Kaplan, Mahesh Parmar, Timothy Perren
The Lancet Oncology. 2015868 CitationsOPEN ACCESS
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, Nobuaki Matsubara, Lajos Géczi, Susanna Cheng, Yves Fradet, Stéphane Oudard, Christof Vulsteke, Rafael Morales‐Barrera, Aude Fléchon, Şeyda Gündüz, Yohann Loriot, Alejo Rodríguez‐Vida, Ronac Mamtani, Evan Y. Yu, Kijoeng Nam, Kentaro Imai, Blanca Homet Moreno, Ajjai Alva, D. Cascallar, Mirta Varela, Mauricio Fernández Lazzaro, Diego Kaen, Gabriela Gatica, David Hugo Flores, Agustín Falco, Matias Molina, F. Van Aelst, Christof Vulsteke, Brieuc Sautois, Jean‐Pascal Machiels, Denis Schallier, Leandro Brust, Liane Rapatoni, Sérgio Jobim Azevedo, GISELE LOPES MARINHO, João Paulo Holanda Soares, Carlos Dzik, Jamile Almeida Silva, André P. Fay, Joel Gingerich, Yves Fradet, Cristiano Ferrario, Kylea Potvin, Marie Vanhuyse, Mahmoud Abdelsalam, Susanna Cheng, Christian Caglevic, Felipe Reyes, José Luis Leal, Francisco Francisco, Carolina Ibáñez, Florence Joly, Brigitte Laguerre, Sylvain Ladoire, Aude Fléchon, Delphine Topart, Olivier Huillard, Stéphane Oudard, Marine Gross‐Goupil, Stéphane Culine, Yohann Loriot, Gwénaëlle Gravis, Peter Reichardt, Margitta Retz, Jan Herden, David G. Pfister, Carsten Ohlman, Michael Stöeckle, Manfred P. Wirth, Anja Lorch, Guenter Niegisch, Peter J. Goebell, Martin Boegemann, Axel S. Merseburger, Georgios Gakis, Jens Bedke, Andreas Neisius, Christian A. Thomas, Thomas Hoefner, András Telekes, Judit Kósa, János Révész, Gyorgy Bodoky, Tibor Csőszi, András Csejtei, Lajos Géczi, Ágnes Ruzsa, Zsuzsanna Kolonics, József Erfán, Ray McDermott, Richard Bambury, Avishay Sella, Stephen Jay Frank, Daniel Kejzman, Olesya Goldman, Eli Rosenbaum, Avivit Peer, Raanan Berger
The Lancet Oncology. 2021655 CitationsOPEN ACCESS
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Ana Oaknin, Tjalling Bosse, Carien L. Creutzberg, Gonzalo Giornelli, Philipp Harter, Florence Joly, Domenica Lorusso, Christian Marth, Vicky Makker, Mansoor Raza Mirza, Jonathan A. Ledermann, Nicoletta Colombo
Annals of Oncology. 2022650 CitationsOPEN ACCESS

Related on ScholarIQ

470M+ articles · free account